![Israel drama and good news for the F-35: Paris Air Show Day 1 [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_1805-scaled-e1750092662883.jpg?#)
![[Updated] Sudden Deployment of Dozens of U.S. Air Force Tankers Raises Questions](https://theaviationist.com/wp-content/uploads/2025/03/Stratotanker100Years_2-e1750080240327.jpg)
Respiratory Syncytial Virus Vaccination
To the Editor The Research Letter by Dr Karaba and colleagues, “Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons,” provides interesting real-world data on the effectiveness of the respiratory syncytial virus (RSV) vaccine in patients with self-reported immunocompromising conditions from a prospective national cohort. The heterogeneity and low immunogenicity response to the vaccine are noteworthy, as 40% of patients did not achieve seroconversion or reach the predefined threshold of neutralizing antibodies. This finding differs from the high overall efficacy that has been described among older adults in the general population (72%-94% and 62%-85.7%, respectively, in 2 studies evaluating prefusion F vaccines).
To the Editor The Research Letter by Dr Karaba and colleagues, “Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons,” provides interesting real-world data on the effectiveness of the respiratory syncytial virus (RSV) vaccine in patients with self-reported immunocompromising conditions from a prospective national cohort. The heterogeneity and low immunogenicity response to the vaccine are noteworthy, as 40% of patients did not achieve seroconversion or reach the predefined threshold of neutralizing antibodies. This finding differs from the high overall efficacy that has been described among older adults in the general population (72%-94% and 62%-85.7%, respectively, in 2 studies evaluating prefusion F vaccines).
